• Home
  • Search Results
  • Genetic Profile of Indian Pheochromocytoma and Paraganglioma Patients - A Single Institutional Study.

Genetic Profile of Indian Pheochromocytoma and Paraganglioma Patients - A Single Institutional Study.

Indian journal of endocrinology and metabolism (2019-11-20)
Gaurav Agarwal, Sendhil Rajan, Ramya C Valiveru, Sonam Tulsyan, Vinita Agrawal, Balraj Mittal, Ghazala Zaidi, Sabaretnam Mayilvaganan, Anjali Mishra, Amit Agarwal, Saroj Kanta Mishra, Eesh Bhatia
ABSTRACT

Pheochromocytomas (PCCs) and Paragangliomas (PGL) are rare catecholamine producing tumors that may present in sporadic or familial settings. Despite vast strides in understanding of PCC/PGL genetics in the last two decades, there is a dearth of information from India. The aim here is to study the prevalence of genetic mutations in Indian PCC/PGL patients. Tertiary care academic hospital; prospective study. 50 histopathologically diagnosed PCC/PGL patients formed the study group. Clinical, biochemical, pathological attributes and outcomes were documented and the phenotype was compared to the genotype. Succinyl dehydrogenase (SDH), Re-Arranged during Transfection (RET), Von-Hippel-Lindau (VHL) and NeuroFibromatosis-1 (NF1) mutations were studied. Additionally, immunohistochemisty for SDHB was also done, and the results compared to mutational analysis of SDH by MLPA (Multiplex Ligation-dependent Probe Activation). Independent samples t-test and Fisher's exact test were used as appropriate. P values ≤0.05 were considered statistically significant. The mean age was 34.3 years. Of the 50 patients, 27 were males and 23 females. 10 patients (20%) in all were detected to have a genetic mutation. 6 patients possessed a RET mutation, while two had VHL mutations. No patient presented with a NF1 mutation. 2 patients had a SDH mutation, and Immunohistochemistry for SDHB correlated with mutational analysis for these patients. The proportion of patients with a familial variant of PCC/PGL is more than what the historic "Rule of Ten" suggests. Our study found that one in five patients have a genetic mutation. PCC/PGL patients with genetic mutations not only require more stringent follow-up, but also screening of family members.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-SDHB antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution